Peripheral T-Cell Lymphomas Pipeline: Advancing Innovation with 40+ Leading Companies Developing Cutting-Edge Therapies | DelveInsight

The Peripheral T-Cell Lymphomas market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, and Akeso Pharmaceuticals. These industry pioneers are transforming treatment strategies and redefining the future of Peripheral T-Cell Lymphomas, bringing new hope to patients worldwide.

DelveInsight's "Peripheral T-Cell Lymphomas Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Peripheral T-Cell Lymphomas market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Peripheral T-Cell Lymphomas drugs, the Peripheral T-Cell Lymphomas pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Peripheral T-Cell Lymphomas Pipeline Report
• DelveInsight's Peripheral T-Cell Lymphomas Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline drugs for Peripheral T-Cell Lymphomas treatment.
• The leading Peripheral T-Cell Lymphomas companies include Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc, and others are evaluating their lead assets to improve the Peripheral T-Cell Lymphomas treatment landscape.
• Key Peripheral T-Cell Lymphomas pipeline therapies in various stages of development include Sarconeos, LPCN 1148, Bimagrumab, FDY 5301, COPIKTRA (duvelisib), Linperlisib, Golidocitinib, Nanatinostat + Valganciclovir, Lacutamab/IPH4102, Sugemalimab, AFM13, Tolinapant, AUTO4, MT-101, KEYTRUDA, OPDIVO, and others.
• In April 2025, Shanghai Yingli Pharmaceutical Co., Ltd. received FDA clearance to begin a global Phase 3 study of linperlisib versus standard care for relapsed/refractory peripheral T-cell lymphoma (PTCL).
• In January 2025, March Biosciences announced that the FDA granted orphan drug designation to MB-105, a first-in-class CD5-targeted CAR-T cell therapy for relapsed/refractory CD5-positive T-cell lymphoma.
• In February 2024, Corvus Pharmaceuticals announced that the FDA granted Orphan Drug Designation for soquelitinib for the treatment of T-cell lymphoma.

Request a sample and discover the recent breakthroughs happening in the Peripheral T-Cell Lymphomas pipeline landscape @ https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral T-Cell Lymphomas Overview
Peripheral T-Cell Lymphomas (PTCL) are a heterogeneous group of aggressive lymphomas that originate from mature T-cells and natural killer (NK) cells. Classified as a subtype of non-Hodgkin's lymphoma (NHL), PTCL affects T-cells specifically, leading to their abnormal development and uncontrolled growth. NHL, in general, impacts two types of white blood cells-B-cells and T-cells-while PTCL is distinguished by its direct effect on T-cells.

Find out more about Peripheral T-Cell Lymphomas medication @ https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral T-Cell Lymphomas Treatment Analysis: Drug Profile
HBI-8000: HUYA Bioscience International
HBI-8000 is an innovative epigenetic therapy belonging to the benzamide class of histone deacetylase inhibitors (HDACIs). It functions by regulating gene expression through the modification of DNA-histone interactions, ultimately influencing various cellular processes that inhibit cancer cell growth, enhance tumor immunity, and modify the tumor microenvironment. Research indicates that this mechanism may also enhance the effectiveness of other cancer therapies, including checkpoint inhibitors.

COPIKTRA (Duvelisib): Secura Bio
COPIKTRA (Duvelisib) is an oral targeted inhibitor of phosphoinositide 3-kinase (PI3K), a critical signaling pathway involved in cancer cell proliferation and metastasis. The drug selectively inhibits the PI3K-delta and PI3K-gamma isoforms, which play key roles in tumor survival and the tumor microenvironment. Duvelisib became the first dual PI3K-d/? inhibitor to receive FDA approval as monotherapy in September 2018 for relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) following at least two prior treatments. In January 2023, the European Commission (EC) granted orphan drug designation (ODD) to duvelisib for the treatment of patients with peripheral T-cell lymphoma (PTCL).

Key Peripheral T-Cell Lymphomas Therapies and Companies
• HBI-8000: HUYA Bioscience International
• COPIKTRA (duvelisib): Secura Bio
• Linperlisib (YY-20394): Shanghai YingLi Pharmaceutical
• Golidocitinib (DZD4205): Dizal Pharmaceuticals
• Nanatinostat + Valganciclovir: Viracta Therapeutics
• Lacutamab/IPH4102: Innate Pharma
• Sugemalimab (CS1001): CStone Pharmaceuticals
• AFM13: Affimed
• Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals
• AUTO4: Autolus
• MT-101: Myeloid Therapeutics

Learn more about the novel and emerging Peripheral T-Cell Lymphomas pipeline therapies @ https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peripheral T-Cell Lymphomas Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Intra-tumoral

By Molecule Type
• Monoclonal antibodies
• Immunoglobulins
• Small molecules
• Pyrimidines
• Proteins and Peptides

Scope of the Peripheral T-Cell Lymphomas Pipeline Report
• Coverage: Global
• Key Peripheral T-Cell Lymphomas Companies: Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc, and others.

• Key Peripheral T-Cell Lymphomas Pipeline Therapies: Sarconeos, LPCN 1148, Bimagrumab, FDY 5301, COPIKTRA (duvelisib), Linperlisib, Golidocitinib, Nanatinostat + Valganciclovir, Lacutamab/IPH4102, Sugemalimab, AFM13, Tolinapant, AUTO4, MT-101, KEYTRUDA, OPDIVO, and others.

Dive deep into rich insights for drugs used for Peripheral T-Cell Lymphomas treatment; visit @ https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Peripheral T-Cell Lymphomas Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Peripheral T-Cell Lymphomas Pipeline Therapeutics
6. Peripheral T-Cell Lymphomas Pipeline: Late-Stage Products (Phase III)
7. Peripheral T-Cell Lymphomas Pipeline: Late-Stage Products (Phase III)
8. Peripheral T-Cell Lymphomas Pipeline: Mid-Stage Products (Phase II)
9. Peripheral T-Cell Lymphomas Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.